MicroRNAs as Prognostic Markers for Chondrogenic Differentiation Potential of Equine Mesenchymal Stromal Cells.


Journal

Stem cells and development
ISSN: 1557-8534
Titre abrégé: Stem Cells Dev
Pays: United States
ID NLM: 101197107

Informations de publication

Date de publication:
Nov 2023
Historique:
medline: 9 11 2023
pubmed: 14 8 2023
entrez: 14 8 2023
Statut: ppublish

Résumé

Mesenchymal stromal cells (MSCs) are a promising cell source for cartilage tissue regeneration in animals and humans but with large interdonor variation in their in vitro chondrogenic differentiation potential. Underlying molecular mechanisms responsible for culture-expanded MSC heterogeneity remain poorly understood. In this study, we sought to identify variations in microRNA (miRNA) signatures associated with cultured equine MSC chondrogenic differentiation potential from different donors. Neocartilage tissue generated from equine cord blood-derived MSCs was categorized as having either high or low chondrogenic potential (LCP) based on their histological appearance and quantification of glycosaminoglycan deposition. Using next-generation sequencing, we identified 30 differentially expressed miRNAs among undifferentiated MSC cultures that corresponded with their chondrogenic potential. Of note, MSCs with LCP upregulated miR-146a and miR-487b-3p, which was also observed by quantitative real-time polymerase chain reaction. Our findings suggest that miRNA profiling of equine MSC cultures may have prognostic value in selecting MSC donors with regard to their chondrogenic differentiation potential.

Identifiants

pubmed: 37578107
doi: 10.1089/scd.2022.0295
doi:

Substances chimiques

MicroRNAs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

693-702

Auteurs

A Hamed Alizadeh (AH)

Department of Biomedical Sciences, University of Guelph, Guelph, Canada.

Starlee Lively (S)

Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Canada.
Krembil Research Institute, University Health Network, Toronto, Canada.

Sarah Lepage (S)

Department of Biomedical Sciences, University of Guelph, Guelph, Canada.

Pratibha Potla (P)

Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Canada.
Krembil Research Institute, University Health Network, Toronto, Canada.

Stewart Russell (S)

Department of Biomedical Sciences, University of Guelph, Guelph, Canada.

Shabana Amanda Ali (SA)

Krembil Research Institute, University Health Network, Toronto, Canada.
Bone and Joint Center, Department of Orthopedic Surgery, Henry Ford Health, Detroit, Michigan, USA.

Mohit Kapoor (M)

Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Canada.
Krembil Research Institute, University Health Network, Toronto, Canada.
Department of Surgery and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.

Thomas G Koch (TG)

Department of Biomedical Sciences, University of Guelph, Guelph, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH